Overview

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

Status:
Completed

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show response to HCTZ 25 mg over a 4-week period.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Hydrochlorothiazide